For research use only. Not for therapeutic Use.
AZD4017 is an investigational drug developed by AstraZeneca, primarily studied for its potential to treat conditions related to excessive cortisol production, such as Cushing’s syndrome. AZD4017 is a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. This enzyme is involved in the conversion of inactive cortisone to active cortisol in tissues. By inhibiting 11β-HSD1, AZD4017 aims to reduce cortisol levels in target tissues, potentially offering therapeutic benefits for conditions associated with hypercortisolism and metabolic disorders. Its development reflects ongoing research into managing diseases linked to cortisol dysregulation.
| Catalog Number | I003410 |
| CAS Number | 1024033-43-9 |
| Molecular Formula | C22H33N3O3S |
| Purity | ≥95% |
| Target | 11β-HSD |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term or -20 °C for long term |
| IUPAC Name | 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid |
| InChI | InChI=1S/C22H33N3O3S/c1-2-13-29-22-18(21(28)23-17-8-4-3-5-9-17)10-11-19(24-22)25-12-6-7-16(15-25)14-20(26)27/h10-11,16-17H,2-9,12-15H2,1H3,(H,23,28)(H,26,27)/t16-/m0/s1 |
| InChIKey | NCDZABJPWMBMIQ-INIZCTEOSA-N |
| SMILES | CCCSC1=C(C=CC(=N1)N2CCCC(C2)CC(=O)O)C(=O)NC3CCCCC3 |
